The Amadeus V Technology Fund invests in Seed and Series A startups that are seeking to improve the way we live, work and interact through science and engineering-led innovation. The fund focuses on:
Artificial Intelligence & Machine Learning
Autonomous Systems & Human Computer Interfaces
Enterprise SaaS & Cyber Security
Digital Health & Medical Technology
Novel Materials & Quantum Technologies
The Amadeus V Technology Fund supports its portfolio companies through advising on the commercialisation of new technologies, applications and materials, recruiting world class teams, and helping startups to secure future investment. Managed by a seasoned team of former entrepreneurs and proven investors with over 50 years’ experience in the successful sourcing, building and exiting of technology companies, the fund has made 16 investments to date, such as:
Xampla – replacing single-use and micro-plastics with plant protein material
Riverlane – Europe’s most advanced quantum software company
XYZ Reality – world’s first ‘Engineering Grade’ Augmented Reality device for construction
Ori Biotech – innovative manufacturing for cell and gene therapy
Commenting on the fund closing, CEO of Amadeus Capital Partners, Anne Glover CBE, said: “The UK has world-leading deep technology innovation, which Amadeus helps to propel into significant global businesses. Amadeus has built its reputation as a deep tech specialist investor over 23 years and, with our roots in Cambridge, London other and innovation clusters across the UK, we are privileged to have access to the most exciting and transformative startups this country has to offer.
“We are pleased that one-third of our early stage investment team are women and, as a female venture capital CEO, I am personally deeply committed to improving diversity among founders and investors in the deep tech space. While the UK is improving, we need more people from diverse backgrounds to be encouraged to embark on the journey from entrepreneurship to financial success and Amadeus is looking forward to backing their innovations in future.”
Judith Hartley, CEO, British Patient Capital added: “Our cornerstone commitment to Amadeus Capital Partners’ latest fund is a key part of our strategy to invest with fund managers that can leverage the UK’s world leading position in science and engineering led innovation. Amadeus’s commitment to Diversity and Inclusion, both in its own team and the companies it backs, is well aligned with British Patient Capital’s mission and values. Long-term patient capital can support our high-potential breakthrough technology companies reach their full potential and deliver compelling returns.”